Thursday, November 15, 2007

Therapeutics of Wegeners Granulomatosis.

Prophylaxis against the most common adverse effects of intervention is an essential motion-picture show of the attention of Wegener’s granulomatosis.
We discuss troika important strategies below. Pneumocystis Pneumonia
One of the subject area side effects of immunosuppressive therapy in patients with Wegener’s granulomatosis is the frequent happening of opportunistic infections, in proposition Pneumocystis jiroveci pneumonia.
Even monotherapy with high-dose glucocorticoids increases the risk of Pneumocystis pathological process. The summation of a cytotoxic factor increases this risk considerably. The use of trimethoprim-sulfamethoxazole (either double-strength, ternary meter per week, or single-strength daily) eliminates Pneumocystis linguistic process as a voltage hinderance.
In patients who are allergic to bactrim, dapsone (100 mg/day), atovaquone (1.5 g/day), or monthly aerosolized pentamidine are all effective alternatives. Cyclophosphamide-induced Cystitis
The risk of drug-induced cystitis and vesica house rises with the cumulative dose of cyclophosphamide.
These complications arise from the toxic effects of a cyclophosphamide metabolite—acrolein—on the urothelium.
Transitional-cell carcinoma of the bag typically occurs gathering after the founding of cyclophosphamide therapy, often long after cyclophosphamide has been discontinued.
In ordination to minimize the diligence of acrolein in the urinary sac and collecting systems, patients should take cyclophosphamide in the dayspring, to avoid prolonged forsaking at Night, and consumption 1.5-2.0 l of substance per day in parliamentary law to maintain brisk diuresis.
An additional therapeutic derivative instrument for the prevention of hemorrhagic cystitis is the use of 2-mercaptoethane sulfonate (MESNA), a chemical compound that binds to and detoxifies acrolein.
Although the data evaluating the efficacy of MESNA as a cure causal agency in cyclophosphamide-treated patients remain unclear, intravenous MESNA is now routinely given during intravenous (intermittent) cyclophosphamide governing body.Osteoporosis
Many patients with Wegener’s granulomatosis are at an increased risk for developing osteoporotic fractures, coil to their prolonged use of glucocorticoids. Patients at risk should be evaluated with a bone mineral spacing musing (e.g.
DUAL-ENERGY X-RAY ABSORPTIOMETRY) to quantify their honor of osteopenia or osteoporosis and consequent risk of fractures.
All patients on glucocorticoids should receive 1.5 g/day of elemental calcium and 700-800 IU/day of vitamin D as safety measures.
This is a part of article Therapeutics of Wegeners Granulomatosis. Taken from "Bactrim Information" Information Blog

No comments: